Sweet dreams: Therapeutic insights, targeting imaging and physiologic evidence linking sleep, melatonin and diabetic nephropathy

6Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Melatonin is the main biochronologic molecular mediator of circadian rhythm and sleep. It is also a powerful antioxidant and has roles in other physiologic pathways. Melatonin deficiency is associated with metabolic derangements including glucose and cholesterol dysregulation, hypertension, disordered sleep and even cancer, likely due to altered immunity. Diabetic nephropathy (DN) is a key microvascular complication of both type 1 and 2 diabetes. DN is the end result of a complex combination of metabolic, haemodynamic, oxidative and inflammatory factors. Interestingly, these same factors have been linked to melatonin deficiency. This report will collate in a clinician-oriented fashion the mechanistic link between melatonin deficiency and factors contributing to DN.

Cite

CITATION STYLE

APA

Afsar, B., Afsar, R. E., Sag, A. A., Kanbay, A., Korkmaz, H., Cipolla-Neto, J., … Kanbay, M. (2020). Sweet dreams: Therapeutic insights, targeting imaging and physiologic evidence linking sleep, melatonin and diabetic nephropathy. Clinical Kidney Journal. Oxford University Press. https://doi.org/10.1093/CKJ/SFZ198

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free